Potassium azeloyl diglycinate
Appears on 0 avoid lists
Included in 208 routines
Summary
- Anti-inflammatory
- Evens skin tone
- Anti-blemish
- Moisturizing
WIMJ Team
A derivative of azelaic acid. It is obtained by reacting the chloride of azelaic acid with two molecules of glycine (an amino acid) and potassium hydroxide. It is less studied than azelaic acid, but the available research suggests that it also can be effective in reducing skin redness, hyperpigmentation and blemishes. There are claims that it is more bio-available and more effective than azelaic acid, but no comparison study is available. Potassium azeloyl diglycinate is better soluble in water compared with azelaic acid. Because of this property, products with potassium azeloyl digclycinate can have a nicer texture
Products with Potassium azeloyl diglycinate
- Exfoliation
- Anti-oxidation
- Anti-aging
- azelaic acid
- retinol
- salicylic acid
- Evens skin tone
- Anti-blemish
- Anti-aging
- niacinamide
- potassium azeloyl diglycinate
- allantoin
- Evens skin tone
- Moisturizing
- Anti-blemish
- lactic acid
- potassium azeloyl diglycinate
- aminobutyric acid
- Evens skin tone
- Anti-aging
- Moisturizing
- niacinamide
- alpha-arbutin
- potassium azeloyl diglycinate
- Anti-aging
- Moisturizing
- Evens skin tone
- niacinamide
- potassium azeloyl diglycinate
- phytosphingosine
- Anti-blemish
- Evens skin tone
- Anti-aging
- niacinamide
- potassium azeloyl diglycinate
- 3-o-ethyl ascorbic acid
- Anti-blemish
- Anti-aging
- Evens skin tone
- salicylic acid
- madecassoside
- retinal
- Evens skin tone
- Anti-aging
- Anti-blemish
- retinal
- salicylic acid
- niacinamide
- Evens skin tone
- Anti-blemish
- Moisturizing
- salicylic acid
- niacinamide
- potassium azeloyl diglycinate
- Anti-blemish
- Cleansing
- Exfoliation
- salicylic acid
- potassium azeloyl diglycinate
- ceramide np
Questions
Clinical trials review
Number of participants | Participants | Interventions | Punchline |
---|---|---|---|
42 | patients of both genders, aged 18–60 years and suffering from stage I and II rosacea. | Patients meeting the inclusion criteria were randomly allocated to P-3075 cream (containing 5% potassium azeloyl diglycinate (Azeloglicina; Sinerga S.p.A., Milan, Italy) and 1% HPCH) or placebo, corresponding to the moisturizing vehicle of the P-3075 cream. Patients were treated twice daily for 28 days (D) with a 2-week follow-up period. The assessments were performed at inclusion (baseline), at D7, D14, D28 (end of treatment), and D42 (end of follow-up). | The mean erythema index in the ancova model showed a statistically significant reduction at the end of treatment in favor of P-3075 in all evaluated facial areas (Fig. 1). A significant decrease in erythema was present from D14 on. |
Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea
Scientifc sources
- Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea
- A Preliminary Clinical Evaluation of a Topical Product for Reducing Slight Rosacea Imperfections
- Azeloyl-Glycine: A new active in skin disequilibrium
- Formulation and evaluation of the cream made from potassium azeloyl diglycinate as an anti-aging